Search Results for "Hypertension"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Hypertension. Results 381 to 390 of 401 total matches.

In Brief: One Drop or Two

   
The Medical Letter on Drugs and Therapeutics • Jun 19, 2006  (Issue 1237)
, thirst, hypokalemia, hypertension, vomiting, diarrhea and orthostatic hypotension have occurred in more ...
Many prescriptions for eye drops call for instillation of 1-2 drops. But Medical Letter consultants in ophthalmology seem to agree that all eye drops should generally be given in doses of only one drop. The volume of a single drop can vary with the viscosity of the solution, the design of the dropper, and patient technique. The average volume of a drop is 35-50 microliters, but can be as high as 75 microliters. An eye brimming with fluid holds 30 microliters at best, so even one drop is often an overdose. A second either washes out the first or increases the possibility of systemic toxicity,...
Med Lett Drugs Ther. 2006 Jun 19;48(1237):49 |  Show IntroductionHide Introduction

Clopidogrel (Plavix) Revisited

   
The Medical Letter on Drugs and Therapeutics • Apr 10, 2006  (Issue 1232)
with aspirin alone in patients with multiple atherothrombotic risk factors (diabetes, hypertension, etc ...
Clopidogrel (Plavix - Sanofi-Aventis and Bristol-Myers Squibb), an oral thienopyridine that inhibits platelet aggregation, is now being advertised directly to the public on television. Clopidogrel is approved by the FDA for secondary prevention of myocardial infarction (MI), stroke and other vascular events and for use in patients with acute coronary syndrome (unstable angina or non-ST-elevation MI), including those undergoing angioplasty. It is used off-label for patients with ST-elevation acute MI
Med Lett Drugs Ther. 2006 Apr 10;48(1232):29-31 |  Show IntroductionHide Introduction

Rasagiline (Azilect) for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Dec 04, 2006  (Issue 1249)
during treatment and for 14 days after rasagiline is discontinued to avoid a possible hypertensive ...
Rasagiline (Azilect - Teva), a monoamine oxidase-type B (MAO-B) inhibitor, was recently approved by the FDA for once-daily oral treatment of Parkinson's disease (PD). It can be taken alone for treatment of early disease or with levodopa/carbidopa (Sinemet, and others) for advanced disease. Selegiline (Eldepryl, and others), the first MAO-B inhibitor marketed in the US, has been available since 1988; a new lower-dose disintegrating tablet (Zelapar) was recently approved.
Med Lett Drugs Ther. 2006 Dec 4;48(1249):97-9 |  Show IntroductionHide Introduction

Drugs for Acne

   
The Medical Letter on Drugs and Therapeutics • Feb 05, 2024  (Issue 1695)
, intracranial hypertension, and hyperpigmentation. CNS effects such as dizziness and vertigo can occur ...
Acne is common among adolescents and adults. Guidelines for treatment of acne were last published by the American Academy of Dermatology in 2016.
Med Lett Drugs Ther. 2024 Feb 5;66(1695):17-20   doi:10.58347/tml.2024.1695a |  Show IntroductionHide Introduction

Comparison Table: Inhaled Drugs for Treatment of COPD (online only)

   
The Medical Letter on Drugs and Therapeutics • Sep 02, 2024  (Issue 1710)
▶ Most common adverse effects include back pain, hypertension, urinary tract infection, and diarrhea ...
View the Comparison Table: Inhaled Drugs for Treatment of COPD
Med Lett Drugs Ther. 2024 Sep 2;66(1710):e143-7   doi:10.58347/tml.2024.1710b |  Show IntroductionHide Introduction

Treatment of Allergic Rhinitis and Allergic Conjunctivitis

   
The Medical Letter on Drugs and Therapeutics • Mar 31, 2025  (Issue 1725)
, hypertension, nausea, vomiting, and urinary retention. They should be used cautiously in patients ...
Initial treatment of allergic rhinitis (AR) depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Med Lett Drugs Ther. 2025 Mar 31;67(1725):49-56   doi:10.58347/tml.2025.1725a |  Show IntroductionHide Introduction

Cannabis and Cannabinoids

   
The Medical Letter on Drugs and Therapeutics • Nov 18, 2019  (Issue 1585)
such as hypotension, hypertension, syncope, or tachycardia can occur with both cannabis and synthetic cannabinoids ...
Cannabis (marijuana) contains more than 60 pharmacologically active cannabinoids; delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best known. THC is the main psychoactive constituent of cannabis. CBD, unlike THC, does not produce intoxication or euphoria.
Med Lett Drugs Ther. 2019 Nov 18;61(1585):179-82 |  Show IntroductionHide Introduction

Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023  (Issue 1680)
and atrioventricular conduction delays can occur when starting ozanimod Hypertension, dose-dependent reductions ...
View the Table: Some Drugs for Inflammatory Bowel Disease
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e115-9   doi:10.58347/tml.2023.1680d |  Show IntroductionHide Introduction

Comparison Table: Some Drugs for Plaque Psoriasis (online only)

   
The Medical Letter on Drugs and Therapeutics • Sep 30, 2024  (Issue 1712)
▶ Doses used for psoriasis are generally safe, but nephrotoxicity and hypertension can occur; use for >1 ...
View the Comparison Table: Some Drugs for Plaque Psoriasis
Med Lett Drugs Ther. 2024 Sep 30;66(1712):e160-6   doi:10.58347/tml.2024.1712b |  Show IntroductionHide Introduction

Drugs for Benign Prostatic Hyperplasia

   
The Medical Letter on Drugs and Therapeutics • May 02, 2022  (Issue 1649)
uncontrolled hypertension (SBP ≥180 mm Hg or DBP ≥110 mm Hg). Leukocytoclastic vasculitis has occurred rarely ...
About 60% of men ≥60 years old have clinically relevant prostatic enlargement due to benign prostatic hyperplasia (BPH). The goals of treatment are to decrease lower urinary tract symptoms and to prevent disease progression and complications such as acute urinary retention. The American Urologic Association's guidelines for treatment of BPH were recently updated.
Med Lett Drugs Ther. 2022 May 2;64(1649):65-9 |  Show IntroductionHide Introduction